SUBSCRIBE
SUBSCRIBE

Johnson & Johnson Family of Companies

NEWS
Pharm Country
Johnson & Johnson Starts Disclosing Drug Unit’s Payments To Doctors
July 9, 2010
 · 
1 min read
Pharm Country
Roche Holding AG, Johnson & Johnson and Biogen Idec, Inc. (Massachusetts) Prodded by FDA for More Neglected Disease Medicines
June 18, 2010
 · 
1 min read
Pharm Country
Drugmakers to Share Data to Speed Brain Drug Research, National Institutes of Health (NIH)
June 11, 2010
 · 
1 min read
Pharm Country
Some Infant Tylenol Recalled by Johnson & Johnson Had Too Much of Active Ingredient
May 19, 2010
 · 
1 min read
Bookmark and Share
BioCapital
Artificial Pancreas Prototype in Development for Type 1 Diabetics By Juvenile Diabetes Research Foundation And Johnson & Johnson
January 14, 2010
 · 
1 min read
Rivaroxaban Drops Pro-Coagulation Factor in HF Patients, Johnson & Johnson Researchers Say
November 16, 2009
 · 
1 min read
BioMidwest
Johnson & Johnson’s Cuts Signal Continued Pressure On Medical Devices
November 4, 2009
 · 
1 min read
Bookmark and Share
Policy
Medical Device Firms Like Johnson & Johnson Warn of Delays From FDA Scrutiny
September 30, 2009
 · 
1 min read
Bookmark and Share
BioCapital
Obama Hospital Deal Will Hurt Medical Device Sales, Johnson & Johnson Says
July 16, 2009
 · 
1 min read
Load More
AWARDS
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies
December 29, 2025
 · 
5 min read
Press Releases
European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor
December 22, 2025
 · 
14 min read
Press Releases
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
December 19, 2025
 · 
6 min read
Press Releases
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
December 18, 2025
 · 
33 min read
Press Releases
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results - December 15, 2025
December 16, 2025
 · 
1 min read
Press Releases
Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors
December 16, 2025
 · 
4 min read
Press Releases
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
December 15, 2025
 · 
20 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
18 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
28 min read
Press Releases
Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 9, 2025
 · 
1 min read
Load More